How much do you need to know the price of Nexavar 200mg Sorafenib ? You do not know where Sorafenib 200mg is sold? index-china is a trading site of Nexavar 200mg Sorafenib in Ho Chi Minh City, Hanoi, Da Nang, Can Tho … and nationwide.
Nexavar medicine 200mg Sorafenib treat with advanced renal cell carcinoma, carcinoma of liver, kidney and thyroid
- Brand name: Nexavar 200mg
- Active ingredient: Sorafenib
- Manufacturer: Bayer Germany
- Content: 200 mg
- Form: Tablets
- Package: Box of 60 tablets
- Nexavar Drug Prices: COMMENT below for prices OR Click on the link: https://thuoclp.com/chatFB type “Nexavar”

What is Nexavar?
- Nexavar is a cancer medicine containing the active ingredient sorafenib. It is available in the form of tablets (200 mg).
- Nexavar (sorafenib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body.
- Nexavar is a targeted therapy. Nexavar is classified as tyrosine kinase inhibitor, angiogenesis inhibitor, and VEGF inhibitor.
Assign nexavar drug
Nexavar is an anti-cancer drug used to treat a certain type of liver, kidney or thyroid cancer called:
- Hepatocellular carcinoma (HCC, a type of liver cancer), when it cannot be treated with surgery
- Kidney cell carcinoma (RCC, a type of kidney cancer)
- Differentiated thyroid carcinoma (DTC, a type of thyroid cancer) can no longer be treated with radioactive iodine and is progressing.
Nexavar has not been studied in children.
The mechanism of action of Nexavar
- The active substance in Nexavar, sorafenib, is a protein kinase inhibitor. This means it blocks certain specific enzymes called protein kinases.
- These enzymes can be found in several receptors on the surface of cancer cells, where they are involved in the growth and spread of cancer cells and in blood vessels that provide tumors, where They participate in the development of new blood vessels.
- By blocking these enzymes, Nexavar can reduce the growth of cancer cells and cut off blood supply to help cancer cells grow.
Dosage of drug Nexavar
- The recommended dose of Nexavar in adults is 2 x 200 mg, twice daily.
- This is equivalent to a daily dose of 800 mg or four capsules daily.
How to use Nexavar
- Swallow Nexavar tablets with a glass of water,
- Do not take this medication with food or high-fat meals, as this can make Nexavar less effective.
- Take medication at least 1 hour before or 2 hours after a meal. Always take this medication exactly as your doctor told you. Check with your doctor or pharmacist if you are unsure.
- It is important to take this medication at about the same time each day, to have a steady amount in the blood.

Warnings about the drug Nexavar
- You should not use Nexavar if you have squamous cell lung cancer and you are being treated with carboplatin (Paraplatin) and paclitaxel (Onxol, Taxol, Abraxane).
- Nexavar may cause heart problems. Stop taking this medicine and call your doctor at once if you have chest pain and severe dizziness, fainting, sweating or feeling short of breath.
- Nexavar can also cause serious bleeding. Call your doctor if you have blood in your urine or stool, unusual vaginal bleeding, severe stomach pain, coughing up blood or any bleeding will not stop.
Careful
- Women avoid pregnancy during treatment with sorafenib.
- Women of childbearing age need to be informed of the potential harm of sorafenib to the fetus, including fetal malformations (teratogens), growth retardation and stillbirth (toxic to embryo).
- Do not use sorafenib while pregnant. Prescription needs to be considered if the benefits outweigh the risks to the fetus.
- Discontinue breastfeeding during treatment with sorafenib.
Nexavar 200mg side effects
- Reactions on the hands and feet (palms, soles of the feet) and rash, these are the most common side effects of sorafenib. Rash and skin reactions on the hands and feet are usually at the level of CTC Grade 1 and 2 common toxicity standards of the National Cancer Institute) and generally appear in the first 6 weeks of sorafenib treatment.
- Treatment of intoxication on the skin may be performed using local measures to relieve symptoms, temporarily discontinue treatment and / or change the dose of sorafenib, or for severe or persistent cases, stop using sorafenib.
- Increased incidence of hypertension has been noted in patients using sorafenib. Hypertension can be mild and moderate, occurs early in the treatment and is easily treated with standard antihypertensive therapy. In case of necessity, regular monitoring and treatment of blood pressure with appropriate drug use regimen. In cases of severe or persistent hypertension should stop using sorafenib.
- An increased risk of bleeding may appear during treatment with sorafenib. Severe bleeding occurs rarely. Serofenib should be discontinued in any case of bleeding requiring medical intervention.
- Abnormal bleeding or an international standard incidence (INR) increase has been reported in some patients taking warfarin concomitantly with sorafebin. These patients should be closely monitored to determine prothrombin time changes, INRs and clinical bleeding (see Adverse effects).
- No official studies have been conducted on the effects of sorafenib during wound healing. In patients undergoing surgery, sorafenib should be temporarily discontinued for caution reasons. The clinical experience of reusing this therapy after surgery is extremely limited. Therefore, when deciding to re-use sorafenib after surgery should be based on clinical assessments suitable for the period of wound healing.
- In the 11213 Study, the incidence of ischemia in the heart and / or myocardial infarction requiring urgent treatment in the sorafenib group (2.9%) was higher than in the placebo group (0.4%). In the 100554 Study, the incidence of ischemia in the heart and / or myocardial infarction requiring urgent treatment in the sorafenib group (2.7%) was higher than in the placebo group (1.3 %). Patients who had unstable coronary artery disease or had a heart attack in the near future were not included in the above studies.
- Temporary or permanent discontinuation of sorafenib should be considered for patients who continue to suffer from ischemia and / or myocardial infarction.
- Perforation is a rare occurrence and is reported to occur in less than 1% of patients using sorafenib. In some cases, this phenomenon is not related to the appearance of a tumor in the abdomen. Sorafenib therapy may be discontinued.
- No data are available for patients with severe hepatic impairment Child-Pugh C. Because sorafenib is mainly excreted through the liver, exposure may be increased in patients with severe hepatic impairment.

Source: index-china.com
How much does Nexafar 200mg Sorafenib cost?
- Please COMMENTS below or Contact index-china 0933049874 (Zalo / Facebook / Viber / Whatsapp) purchase and sale of brand-name drugs in HCM City, Hanoi, Da Nang City, Can Tho, … Nationwide
Where to buy Nexavar 200mg Sorafenib?
- Please COMMENTS below or Contact index-china 0933049874 (Zalo / Facebook / Viber / Whatsapp) purchase and sale of brand-name drugs in HCM City, Hanoi, Da Nang City, Can Tho, … Nationwide
Watch the Nexavar drug 200mg 60 tablets
Nexavar medicine 200mg Sorafenib treat with advanced renal cell carcinoma, carcinoma of liver, kidney and thyroid.
Contact index-china 0933049874 drugs (Zalo / Facebook / Viber) buy and sell brand name drugs in Ho Chi Minh City, Hanoi, Danang City, Can Tho City, … nationwide
Assoc.Prof.Dr. Tran Ngoc Anh is currently Hanoi Medical University Hospital, Associate Professor, Department of Internal Medicine, Gastroenterology and Head of Department of General-Uematology of Hanoi Medical University. Consulting doctor at ThuocLP Pharmacy.
Professional qualifications, Academic degrees – Education:
Graduated from General Practitioner System, Hanoi Medical University
Graduated with a Master degree in Internal Medicine, Hanoi Medical University
Graduated from the training program specialized in Gastrointestinal, Henri Mondor Institute Center, University of Paris 6, French Republic 1996-1997; 1999
Graduated from the training program specialized in Gastrointestinal, North Royal Sydney Hospital, Australia; 2002
Graduated from a training program specialized in chronic liver diseases, Pizza, Italy 2009
Graduated with a PhD in Gastrointestinal, Hanoi Medical University
Associate Professor, Gastroenterology, Hanoi Medical University
Training and Scientific Research:
Published more than 200 articles in domestic and international specialized journals
Editor of many monographs and participates in compiling 2 textbooks.
Guide many students and graduate students of Hanoi Medical University
Manager of many grassroots research projects
Medical Certificate:
Certificate of Good Clinical Practice (GCP: 2012, 2015), Ministry of Health
Specialized certificates: General gastrointestinal endoscopy, Interventional gastrointestinal endoscopy, General gastrointestinal ultrasound, Interventional gastrointestinal ultrasound (Bach Mai BV), Chronic liver disease.
Reviews
There are no reviews yet.